 | • レポートコード：MRC2Q12-19280 • 出版社/出版日：QYResearch / 2022年12月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、127ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医薬品＆医療 |
| Single User | ￥710,500 (USD4,900) | ▷ お問い合わせ |
| Enterprise License | ￥1,421,000 (USD9,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 新型コロナウイルス感染症とロシア・ウクライナ戦争の影響により、非麻薬性鎮痛薬のグローバル市場は 2022にxxxドルと推定され、2028年までにxxxドルの規模に達し、2022年から2028年の予測期間中にxxx%のCAGRで成長すると予測されています。 非麻薬性鎮痛薬のアメリカ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 非麻薬性鎮痛薬の中国市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 非麻薬性鎮痛薬のヨーロッパ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 生産面において、本レポートは2017年から2022年までの非麻薬性鎮痛薬の生産、成長率、メーカー別市場シェア、地域別市場シェア、および2028年までの予測を調査しています。販売面において、本レポートは2017年から2022年までの地域別、企業別、タイプ別、アプリケーション別の非麻薬性鎮痛薬の売上および2028年までの予測に焦点を当てています。 非麻薬性鎮痛薬のグローバル主要企業には、GlaxoSmithKline Consumer Healthcare、Bayer Corporation、Atnahs Pharma、Baudax Bio、Prestige Brands, Inc.、Cumberland Pharmaceuticals, Inc.、Takeda Pharmaceutical Company、Pfizer Inc.、McNeil Consumer Healthcare、Eli Lilly and Company、Sun Pharmaceutical Industries、Validus Pharmaceuticals、Novartis Consumer Health、Pacira Pharmaceuticals, Inc.、Almatica Pharma、Actavis、Arbor Pharmaceuticals, LLC、PLx Pharma Inc.、Heron Therapeutics、Assertio Therapeutics, Inc.、Zyla Life Sciences、Jazz Pharmaceuticals plcなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 非麻薬性鎮痛薬市場は、タイプとアプリケーションによって区分されます。世界の非麻薬性鎮痛薬市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別およびアプリケーション別の販売量、売上、予測に焦点を当てています。 【タイプ別セグメント】 サリチル酸、アニリン、ピラゾロン、その他 【アプリケーション別セグメント】 病院、薬局、専門医院、その他 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - 非麻薬性鎮痛薬製品概要 - タイプ別市場（サリチル酸、アニリン、ピラゾロン、その他） - アプリケーション別市場（病院、薬局、専門医院、その他） - 調査の目的 ・エグゼクティブサマリー - 世界の非麻薬性鎮痛薬販売量予測2017-2028 - 世界の非麻薬性鎮痛薬売上予測2017-2028 - 非麻薬性鎮痛薬の地域別販売量 - 非麻薬性鎮痛薬の地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別非麻薬性鎮痛薬販売量 - 主要メーカー別非麻薬性鎮痛薬売上 - 主要メーカー別非麻薬性鎮痛薬価格 - 競争状況の分析 - 企業M&A動向 ・タイプ別市場規模（サリチル酸、アニリン、ピラゾロン、その他） - 非麻薬性鎮痛薬のタイプ別販売量 - 非麻薬性鎮痛薬のタイプ別売上 - 非麻薬性鎮痛薬のタイプ別価格 ・アプリケーション別市場規模（病院、薬局、専門医院、その他） - 非麻薬性鎮痛薬のアプリケーション別販売量 - 非麻薬性鎮痛薬のアプリケーション別売上 - 非麻薬性鎮痛薬のアプリケーション別価格 ・北米市場 - 北米の非麻薬性鎮痛薬市場規模（タイプ別、アプリケーション別） - 主要国別の非麻薬性鎮痛薬市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパの非麻薬性鎮痛薬市場規模（タイプ別、アプリケーション別） - 主要国別の非麻薬性鎮痛薬市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋の非麻薬性鎮痛薬市場規模（タイプ別、アプリケーション別） - 主要国別の非麻薬性鎮痛薬市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米の非麻薬性鎮痛薬市場規模（タイプ別、アプリケーション別） - 主要国別の非麻薬性鎮痛薬市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカの非麻薬性鎮痛薬市場規模（タイプ別、アプリケーション別） - 主要国別の非麻薬性鎮痛薬市場規模（トルコ、サウジアラビア） ・企業情報 GlaxoSmithKline Consumer Healthcare、Bayer Corporation、Atnahs Pharma、Baudax Bio、Prestige Brands, Inc.、Cumberland Pharmaceuticals, Inc.、Takeda Pharmaceutical Company、Pfizer Inc.、McNeil Consumer Healthcare、Eli Lilly and Company、Sun Pharmaceutical Industries、Validus Pharmaceuticals、Novartis Consumer Health、Pacira Pharmaceuticals, Inc.、Almatica Pharma、Actavis、Arbor Pharmaceuticals, LLC、PLx Pharma Inc.、Heron Therapeutics、Assertio Therapeutics, Inc.、Zyla Life Sciences、Jazz Pharmaceuticals plc ・産業チェーン及び販売チャネル分析 - 非麻薬性鎮痛薬の産業チェーン分析 - 非麻薬性鎮痛薬の原材料 - 非麻薬性鎮痛薬の生産プロセス - 非麻薬性鎮痛薬の販売及びマーケティング - 非麻薬性鎮痛薬の主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - 非麻薬性鎮痛薬の産業動向 - 非麻薬性鎮痛薬のマーケットドライバー - 非麻薬性鎮痛薬の課題 - 非麻薬性鎮痛薬の阻害要因 ・主な調査結果 |
Nonnarcotic analgesics refer to non steroidal anti-inflammatory drugs that have nothing to do with or have little to do with central opioid receptors
Report Overview
Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Product Name estimated at US$ million in the year 2022, is projected to reach a revised size of US$ million by 2028, growing at a CAGR of % during the forecast period 2022-2028.
The USA market for Nonnarcotic Analgesics is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The China market for Nonnarcotic Analgesics is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The Europe market for Nonnarcotic Analgesics is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The global key manufacturers of Nonnarcotic Analgesics include GlaxoSmithKline Consumer Healthcare, Bayer Corporation, Atnahs Pharma, Baudax Bio, Prestige Brands, Inc., Cumberland Pharmaceuticals, Inc., Takeda Pharmaceutical Company, Pfizer Inc. and McNeil Consumer Healthcare, etc. In 2021, the global top five players had a share approximately % in terms of revenue.
Report Scope
This latest report researches the industry structure, sales, revenue, price and gross margin. Major producers’ production locations, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Nonnarcotic Analgesics manufacturers, distributors, end users, industry associations, governments’ industry bureaus, industry publications, industry experts, third party database, and our in-house databases.
This report also includes a discussion of the major players across each regional Nonnarcotic Analgesics market. Further, it explains the major drivers and regional dynamics of the global Nonnarcotic Analgesics market and current trends within the industry.
Key Companies Covered
In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and market share analysis of the prominent players are also provided in this section. Additionally, the specialists have done an all-encompassing analysis of each player. They have also provided reliable sales, revenue, price, market share and rank data of the manufacturers for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:
GlaxoSmithKline Consumer Healthcare
Bayer Corporation
Atnahs Pharma
Baudax Bio
Prestige Brands, Inc.
Cumberland Pharmaceuticals, Inc.
Takeda Pharmaceutical Company
Pfizer Inc.
McNeil Consumer Healthcare
Eli Lilly and Company
Sun Pharmaceutical Industries
Validus Pharmaceuticals
Novartis Consumer Health
Pacira Pharmaceuticals, Inc.
Almatica Pharma
Actavis
Arbor Pharmaceuticals, LLC
PLx Pharma Inc.
Heron Therapeutics
Assertio Therapeutics, Inc.
Zyla Life Sciences
Jazz Pharmaceuticals plc
Market Segments
This report has explored the key segments: by Type and by Application. The lucrativeness and growth potential have been looked into by the industry experts in this report. This report also provides sales, revenue and average price forecast data by type and by application segments based on sales, price, and value for the period 2017-2028.
Nonnarcotic Analgesics Segment by Type
Salicylates
Anilines
Pyrazolones
Other Organic Acids
Nonnarcotic Analgesics Segment by Application
Hospital
Pharmacy
Specialist Clinic
Other
Key Regions & Countries
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the value and sales data of each region and country for the period 2017-2028.
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Nonnarcotic Analgesics market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Report Includes:
This report presents an overview of global market for Nonnarcotic Analgesics, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2017 – 2021, estimates for 2022, and projections of CAGR through 2028.
This report researches the key producers of Nonnarcotic Analgesics, also provides the sales of main regions and countries. Highlights of the upcoming market potential for Nonnarcotic Analgesics, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Nonnarcotic Analgesics sales, revenue, market share and industry ranking of main manufacturers, data from 2017 to 2022. Identification of the major stakeholders in the global Nonnarcotic Analgesics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, sales, revenue, and price, from 2017 to 2028. Evaluation and forecast the market size for Nonnarcotic Analgesics sales, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including GlaxoSmithKline Consumer Healthcare, Bayer Corporation, Atnahs Pharma, Baudax Bio, Prestige Brands, Inc., Cumberland Pharmaceuticals, Inc., Takeda Pharmaceutical Company, Pfizer Inc. and McNeil Consumer Healthcare, etc.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of Nonnarcotic Analgesics in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 3: Detailed analysis of Nonnarcotic Analgesics manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments according to product types, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments according to application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by type, by application and by country, sales and revenue for each segment.
Chapter 7: Europe by type, by application and by country, sales and revenue for each segment.
Chapter 8: Asia Pacific by type, by application and by country, sales and revenue for each segment.
Chapter 9: Latin America by type, by application and by country, sales and revenue for each segment.
Chapter 10: Middle East and Africa by type, by application and by country, sales and revenue for each segment.
Chapter 11: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Nonnarcotic Analgesics sales, revenue, price, gross margin, and recent development, etc.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: The main points and conclusions of the report.
1 Study Coverage
1.1 Nonnarcotic Analgesics Product Introduction
1.2 Market by Type
1.2.1 Global Nonnarcotic Analgesics Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Salicylates
1.2.3 Anilines
1.2.4 Pyrazolones
1.2.5 Other Organic Acids
1.3 Market by Application
1.3.1 Global Nonnarcotic Analgesics Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospital
1.3.3 Pharmacy
1.3.4 Specialist Clinic
1.3.5 Other
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Nonnarcotic Analgesics Sales Estimates and Forecasts 2017-2028
2.2 Global Nonnarcotic Analgesics Revenue Estimates and Forecasts 2017-2028
2.3 Global Nonnarcotic Analgesics Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Nonnarcotic Analgesics Sales by Region
2.4.1 Global Nonnarcotic Analgesics Sales by Region (2017-2022)
2.4.2 Global Sales Nonnarcotic Analgesics by Region (2023-2028)
2.5 Global Nonnarcotic Analgesics Revenue by Region
2.5.1 Global Nonnarcotic Analgesics Revenue by Region (2017-2022)
2.5.2 Global Nonnarcotic Analgesics Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Nonnarcotic Analgesics Sales by Manufacturers
3.1.1 Global Top Nonnarcotic Analgesics Manufacturers by Sales (2017-2022)
3.1.2 Global Nonnarcotic Analgesics Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Nonnarcotic Analgesics in 2021
3.2 Global Nonnarcotic Analgesics Revenue by Manufacturers
3.2.1 Global Nonnarcotic Analgesics Revenue by Manufacturers (2017-2022)
3.2.2 Global Nonnarcotic Analgesics Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Nonnarcotic Analgesics Revenue in 2021
3.3 Global Nonnarcotic Analgesics Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Nonnarcotic Analgesics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Nonnarcotic Analgesics Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Nonnarcotic Analgesics Sales by Type
4.1.1 Global Nonnarcotic Analgesics Historical Sales by Type (2017-2022)
4.1.2 Global Nonnarcotic Analgesics Forecasted Sales by Type (2023-2028)
4.1.3 Global Nonnarcotic Analgesics Sales Market Share by Type (2017-2028)
4.2 Global Nonnarcotic Analgesics Revenue by Type
4.2.1 Global Nonnarcotic Analgesics Historical Revenue by Type (2017-2022)
4.2.2 Global Nonnarcotic Analgesics Forecasted Revenue by Type (2023-2028)
4.2.3 Global Nonnarcotic Analgesics Revenue Market Share by Type (2017-2028)
4.3 Global Nonnarcotic Analgesics Price by Type
4.3.1 Global Nonnarcotic Analgesics Price by Type (2017-2022)
4.3.2 Global Nonnarcotic Analgesics Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Nonnarcotic Analgesics Sales by Application
5.1.1 Global Nonnarcotic Analgesics Historical Sales by Application (2017-2022)
5.1.2 Global Nonnarcotic Analgesics Forecasted Sales by Application (2023-2028)
5.1.3 Global Nonnarcotic Analgesics Sales Market Share by Application (2017-2028)
5.2 Global Nonnarcotic Analgesics Revenue by Application
5.2.1 Global Nonnarcotic Analgesics Historical Revenue by Application (2017-2022)
5.2.2 Global Nonnarcotic Analgesics Forecasted Revenue by Application (2023-2028)
5.2.3 Global Nonnarcotic Analgesics Revenue Market Share by Application (2017-2028)
5.3 Global Nonnarcotic Analgesics Price by Application
5.3.1 Global Nonnarcotic Analgesics Price by Application (2017-2022)
5.3.2 Global Nonnarcotic Analgesics Price Forecast by Application (2023-2028)
6 North America
6.1 North America Nonnarcotic Analgesics Market Size by Type
6.1.1 North America Nonnarcotic Analgesics Sales by Type (2017-2028)
6.1.2 North America Nonnarcotic Analgesics Revenue by Type (2017-2028)
6.2 North America Nonnarcotic Analgesics Market Size by Application
6.2.1 North America Nonnarcotic Analgesics Sales by Application (2017-2028)
6.2.2 North America Nonnarcotic Analgesics Revenue by Application (2017-2028)
6.3 North America Nonnarcotic Analgesics Market Size by Country
6.3.1 North America Nonnarcotic Analgesics Sales by Country (2017-2028)
6.3.2 North America Nonnarcotic Analgesics Revenue by Country (2017-2028)
6.3.3 United States
6.3.4 Canada
7 Europe
7.1 Europe Nonnarcotic Analgesics Market Size by Type
7.1.1 Europe Nonnarcotic Analgesics Sales by Type (2017-2028)
7.1.2 Europe Nonnarcotic Analgesics Revenue by Type (2017-2028)
7.2 Europe Nonnarcotic Analgesics Market Size by Application
7.2.1 Europe Nonnarcotic Analgesics Sales by Application (2017-2028)
7.2.2 Europe Nonnarcotic Analgesics Revenue by Application (2017-2028)
7.3 Europe Nonnarcotic Analgesics Market Size by Country
7.3.1 Europe Nonnarcotic Analgesics Sales by Country (2017-2028)
7.3.2 Europe Nonnarcotic Analgesics Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Nonnarcotic Analgesics Market Size by Type
8.1.1 Asia Pacific Nonnarcotic Analgesics Sales by Type (2017-2028)
8.1.2 Asia Pacific Nonnarcotic Analgesics Revenue by Type (2017-2028)
8.2 Asia Pacific Nonnarcotic Analgesics Market Size by Application
8.2.1 Asia Pacific Nonnarcotic Analgesics Sales by Application (2017-2028)
8.2.2 Asia Pacific Nonnarcotic Analgesics Revenue by Application (2017-2028)
8.3 Asia Pacific Nonnarcotic Analgesics Market Size by Region
8.3.1 Asia Pacific Nonnarcotic Analgesics Sales by Region (2017-2028)
8.3.2 Asia Pacific Nonnarcotic Analgesics Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 China Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
9 Latin America
9.1 Latin America Nonnarcotic Analgesics Market Size by Type
9.1.1 Latin America Nonnarcotic Analgesics Sales by Type (2017-2028)
9.1.2 Latin America Nonnarcotic Analgesics Revenue by Type (2017-2028)
9.2 Latin America Nonnarcotic Analgesics Market Size by Application
9.2.1 Latin America Nonnarcotic Analgesics Sales by Application (2017-2028)
9.2.2 Latin America Nonnarcotic Analgesics Revenue by Application (2017-2028)
9.3 Latin America Nonnarcotic Analgesics Market Size by Country
9.3.1 Latin America Nonnarcotic Analgesics Sales by Country (2017-2028)
9.3.2 Latin America Nonnarcotic Analgesics Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
9.3.6 Colombia
10 Middle East and Africa
10.1 Middle East and Africa Nonnarcotic Analgesics Market Size by Type
10.1.1 Middle East and Africa Nonnarcotic Analgesics Sales by Type (2017-2028)
10.1.2 Middle East and Africa Nonnarcotic Analgesics Revenue by Type (2017-2028)
10.2 Middle East and Africa Nonnarcotic Analgesics Market Size by Application
10.2.1 Middle East and Africa Nonnarcotic Analgesics Sales by Application (2017-2028)
10.2.2 Middle East and Africa Nonnarcotic Analgesics Revenue by Application (2017-2028)
10.3 Middle East and Africa Nonnarcotic Analgesics Market Size by Country
10.3.1 Middle East and Africa Nonnarcotic Analgesics Sales by Country (2017-2028)
10.3.2 Middle East and Africa Nonnarcotic Analgesics Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 GlaxoSmithKline Consumer Healthcare
11.1.1 GlaxoSmithKline Consumer Healthcare Corporation Information
11.1.2 GlaxoSmithKline Consumer Healthcare Overview
11.1.3 GlaxoSmithKline Consumer Healthcare Nonnarcotic Analgesics Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 GlaxoSmithKline Consumer Healthcare Nonnarcotic Analgesics Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 GlaxoSmithKline Consumer Healthcare Recent Developments
11.2 Bayer Corporation
11.2.1 Bayer Corporation Corporation Information
11.2.2 Bayer Corporation Overview
11.2.3 Bayer Corporation Nonnarcotic Analgesics Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Bayer Corporation Nonnarcotic Analgesics Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Bayer Corporation Recent Developments
11.3 Atnahs Pharma
11.3.1 Atnahs Pharma Corporation Information
11.3.2 Atnahs Pharma Overview
11.3.3 Atnahs Pharma Nonnarcotic Analgesics Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Atnahs Pharma Nonnarcotic Analgesics Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Atnahs Pharma Recent Developments
11.4 Baudax Bio
11.4.1 Baudax Bio Corporation Information
11.4.2 Baudax Bio Overview
11.4.3 Baudax Bio Nonnarcotic Analgesics Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Baudax Bio Nonnarcotic Analgesics Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Baudax Bio Recent Developments
11.5 Prestige Brands, Inc.
11.5.1 Prestige Brands, Inc. Corporation Information
11.5.2 Prestige Brands, Inc. Overview
11.5.3 Prestige Brands, Inc. Nonnarcotic Analgesics Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Prestige Brands, Inc. Nonnarcotic Analgesics Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Prestige Brands, Inc. Recent Developments
11.6 Cumberland Pharmaceuticals, Inc.
11.6.1 Cumberland Pharmaceuticals, Inc. Corporation Information
11.6.2 Cumberland Pharmaceuticals, Inc. Overview
11.6.3 Cumberland Pharmaceuticals, Inc. Nonnarcotic Analgesics Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Cumberland Pharmaceuticals, Inc. Nonnarcotic Analgesics Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Cumberland Pharmaceuticals, Inc. Recent Developments
11.7 Takeda Pharmaceutical Company
11.7.1 Takeda Pharmaceutical Company Corporation Information
11.7.2 Takeda Pharmaceutical Company Overview
11.7.3 Takeda Pharmaceutical Company Nonnarcotic Analgesics Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 Takeda Pharmaceutical Company Nonnarcotic Analgesics Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Takeda Pharmaceutical Company Recent Developments
11.8 Pfizer Inc.
11.8.1 Pfizer Inc. Corporation Information
11.8.2 Pfizer Inc. Overview
11.8.3 Pfizer Inc. Nonnarcotic Analgesics Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 Pfizer Inc. Nonnarcotic Analgesics Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Pfizer Inc. Recent Developments
11.9 McNeil Consumer Healthcare
11.9.1 McNeil Consumer Healthcare Corporation Information
11.9.2 McNeil Consumer Healthcare Overview
11.9.3 McNeil Consumer Healthcare Nonnarcotic Analgesics Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 McNeil Consumer Healthcare Nonnarcotic Analgesics Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 McNeil Consumer Healthcare Recent Developments
11.10 Eli Lilly and Company
11.10.1 Eli Lilly and Company Corporation Information
11.10.2 Eli Lilly and Company Overview
11.10.3 Eli Lilly and Company Nonnarcotic Analgesics Sales, Price, Revenue and Gross Margin (2017-2022)
11.10.4 Eli Lilly and Company Nonnarcotic Analgesics Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Eli Lilly and Company Recent Developments
11.11 Sun Pharmaceutical Industries
11.11.1 Sun Pharmaceutical Industries Corporation Information
11.11.2 Sun Pharmaceutical Industries Overview
11.11.3 Sun Pharmaceutical Industries Nonnarcotic Analgesics Sales, Price, Revenue and Gross Margin (2017-2022)
11.11.4 Sun Pharmaceutical Industries Nonnarcotic Analgesics Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Sun Pharmaceutical Industries Recent Developments
11.12 Validus Pharmaceuticals
11.12.1 Validus Pharmaceuticals Corporation Information
11.12.2 Validus Pharmaceuticals Overview
11.12.3 Validus Pharmaceuticals Nonnarcotic Analgesics Sales, Price, Revenue and Gross Margin (2017-2022)
11.12.4 Validus Pharmaceuticals Nonnarcotic Analgesics Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 Validus Pharmaceuticals Recent Developments
11.13 Novartis Consumer Health
11.13.1 Novartis Consumer Health Corporation Information
11.13.2 Novartis Consumer Health Overview
11.13.3 Novartis Consumer Health Nonnarcotic Analgesics Sales, Price, Revenue and Gross Margin (2017-2022)
11.13.4 Novartis Consumer Health Nonnarcotic Analgesics Product Model Numbers, Pictures, Descriptions and Specifications
11.13.5 Novartis Consumer Health Recent Developments
11.14 Pacira Pharmaceuticals, Inc.
11.14.1 Pacira Pharmaceuticals, Inc. Corporation Information
11.14.2 Pacira Pharmaceuticals, Inc. Overview
11.14.3 Pacira Pharmaceuticals, Inc. Nonnarcotic Analgesics Sales, Price, Revenue and Gross Margin (2017-2022)
11.14.4 Pacira Pharmaceuticals, Inc. Nonnarcotic Analgesics Product Model Numbers, Pictures, Descriptions and Specifications
11.14.5 Pacira Pharmaceuticals, Inc. Recent Developments
11.15 Almatica Pharma
11.15.1 Almatica Pharma Corporation Information
11.15.2 Almatica Pharma Overview
11.15.3 Almatica Pharma Nonnarcotic Analgesics Sales, Price, Revenue and Gross Margin (2017-2022)
11.15.4 Almatica Pharma Nonnarcotic Analgesics Product Model Numbers, Pictures, Descriptions and Specifications
11.15.5 Almatica Pharma Recent Developments
11.16 Actavis
11.16.1 Actavis Corporation Information
11.16.2 Actavis Overview
11.16.3 Actavis Nonnarcotic Analgesics Sales, Price, Revenue and Gross Margin (2017-2022)
11.16.4 Actavis Nonnarcotic Analgesics Product Model Numbers, Pictures, Descriptions and Specifications
11.16.5 Actavis Recent Developments
11.17 Arbor Pharmaceuticals, LLC
11.17.1 Arbor Pharmaceuticals, LLC Corporation Information
11.17.2 Arbor Pharmaceuticals, LLC Overview
11.17.3 Arbor Pharmaceuticals, LLC Nonnarcotic Analgesics Sales, Price, Revenue and Gross Margin (2017-2022)
11.17.4 Arbor Pharmaceuticals, LLC Nonnarcotic Analgesics Product Model Numbers, Pictures, Descriptions and Specifications
11.17.5 Arbor Pharmaceuticals, LLC Recent Developments
11.18 PLx Pharma Inc.
11.18.1 PLx Pharma Inc. Corporation Information
11.18.2 PLx Pharma Inc. Overview
11.18.3 PLx Pharma Inc. Nonnarcotic Analgesics Sales, Price, Revenue and Gross Margin (2017-2022)
11.18.4 PLx Pharma Inc. Nonnarcotic Analgesics Product Model Numbers, Pictures, Descriptions and Specifications
11.18.5 PLx Pharma Inc. Recent Developments
11.19 Heron Therapeutics
11.19.1 Heron Therapeutics Corporation Information
11.19.2 Heron Therapeutics Overview
11.19.3 Heron Therapeutics Nonnarcotic Analgesics Sales, Price, Revenue and Gross Margin (2017-2022)
11.19.4 Heron Therapeutics Nonnarcotic Analgesics Product Model Numbers, Pictures, Descriptions and Specifications
11.19.5 Heron Therapeutics Recent Developments
11.20 Assertio Therapeutics, Inc.
11.20.1 Assertio Therapeutics, Inc. Corporation Information
11.20.2 Assertio Therapeutics, Inc. Overview
11.20.3 Assertio Therapeutics, Inc. Nonnarcotic Analgesics Sales, Price, Revenue and Gross Margin (2017-2022)
11.20.4 Assertio Therapeutics, Inc. Nonnarcotic Analgesics Product Model Numbers, Pictures, Descriptions and Specifications
11.20.5 Assertio Therapeutics, Inc. Recent Developments
11.21 Zyla Life Sciences
11.21.1 Zyla Life Sciences Corporation Information
11.21.2 Zyla Life Sciences Overview
11.21.3 Zyla Life Sciences Nonnarcotic Analgesics Sales, Price, Revenue and Gross Margin (2017-2022)
11.21.4 Zyla Life Sciences Nonnarcotic Analgesics Product Model Numbers, Pictures, Descriptions and Specifications
11.21.5 Zyla Life Sciences Recent Developments
11.22 Jazz Pharmaceuticals plc
11.22.1 Jazz Pharmaceuticals plc Corporation Information
11.22.2 Jazz Pharmaceuticals plc Overview
11.22.3 Jazz Pharmaceuticals plc Nonnarcotic Analgesics Sales, Price, Revenue and Gross Margin (2017-2022)
11.22.4 Jazz Pharmaceuticals plc Nonnarcotic Analgesics Product Model Numbers, Pictures, Descriptions and Specifications
11.22.5 Jazz Pharmaceuticals plc Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Nonnarcotic Analgesics Industry Chain Analysis
12.2 Nonnarcotic Analgesics Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Nonnarcotic Analgesics Production Mode & Process
12.4 Nonnarcotic Analgesics Sales and Marketing
12.4.1 Nonnarcotic Analgesics Sales Channels
12.4.2 Nonnarcotic Analgesics Distributors
12.5 Nonnarcotic Analgesics Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Nonnarcotic Analgesics Industry Trends
13.2 Nonnarcotic Analgesics Market Drivers
13.3 Nonnarcotic Analgesics Market Challenges
13.4 Nonnarcotic Analgesics Market Restraints
14 Key Findings in The Global Nonnarcotic Analgesics Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
| 【非麻薬性鎮痛薬について】 非麻薬性鎮痛薬は、痛みを軽減するために使用される医薬品の一群であり、麻薬に依存しない薬剤として分類されます。これらは、主に軽度から中等度の痛みを緩和する目的で使用され、麻薬性鎮痛薬と比べて副作用が少ないのが特徴です。非麻薬性鎮痛薬の理解を深めるために、定義、特徴、種類、用途、関連技術などについて詳しく説明いたします。 非麻薬性鎮痛薬の定義は、主に痛みを緩和するための薬剤であり、麻薬性成分を含まないものを指します。これらの薬剤は中枢神経系に作用して痛みの感じ方を変化させるのではなく、主に末梢での疼痛受容体に作用することで効果を発揮します。また、非麻薬性鎮痛薬は、一般的に依存性が低く、長期的に使用しても耐性の形成が少ないため、患者にとって安全な選択肢とされています。 非麻薬性鎮痛薬の特徴には、多くの種類があること、効果の発現が比較的早いこと、副作用が少ないこと、そして、使用が比較的容易であることが挙げられます。これらの薬剤は、オーバー・ザ・カウンター（OTC）で購入できるものも多く、自己管理が可能なことから、患者が手軽に痛みを緩和する手段を持つことができます。さらに、非麻薬性鎮痛薬は、低用量から中用量で使用されるため、副作用を抑えることができる点も重要です。 非麻薬性鎮痛薬の代表的な種類には、アセトアミノフェン、非ステロイド性抗炎症薬（NSAIDs）、サリチル酸塩、選択的COX-2阻害薬などがあります。 アセトアミノフェンは、非常に一般的な非麻薬性鎮痛薬であり、軽度から中等度の痛みを和らげるために使用されます。抗炎症作用はありませんが、解熱作用があり、風邪やインフルエンザなどの症状緩和にも使用されます。主な副作用は肝障害やアレルギー反応ですが、適切な用量で使用する限り、比較的安全とされています。 非ステロイド性抗炎症薬（NSAIDs）は、炎症を抑えるだけでなく、痛みの緩和にも優れた効果を持つ薬剤です。これらは、痛みの原因となるプロスタグランジンの生成を抑えることで効果を発揮します。代表的なNSAIDsには、イブプロフェン、ナプロキセン、ジクロフェナクなどがあり、関節炎や筋肉痛、頭痛、歯痛など、さまざまな痛みに用いられます。ただし、長期間の使用は消化管や腎臓への影響が懸念されるため、注意が必要です。 サリチル酸塩は、アスピリンが代表的な非麻薬性鎮痛薬の一つで、解熱、抗炎症、鎮痛作用を持っています。特に心血管疾患の予防に使用されることがありますが、出血のリスクがあるため、使用には注意が必要です。 選択的COX-2阻害薬は、通常のNSAIDsとは異なり、COX-2と呼ばれる炎症に関与する酵素を選択的に阻害することで、痛みと炎症を緩和する薬剤です。これにより、従来のNSAIDsに比べて消化管への副作用が少ないとされていますが、心血管リスクが増加する可能性があるため、使用する際は医師の指導が必要です。 非麻薬性鎮痛薬の用途は広範であり、日常生活におけるさまざまな痛みの管理に利用されます。例えば、頭痛、筋肉痛、関節痛、生理痛、歯痛、風邪やインフルエンザによる軽微な痛みや発熱に使用されることが多いです。また、手術後の痛みの管理や慢性的な痛みのコントロールにも寄与することがあります。 関連技術として、非麻薬性鎮痛薬の効果を高めるための研究や、痛みのメカニズムに関する知識の深化が進められています。また、痛みの予測や管理を支えるためのデジタルヘルス技術や患者の自己管理支援アプリケーションの開発も進行中です。これにより、患者は自分の症状や薬剤の効果についてより良い理解を持つことができ、自らの健康管理に積極的に携わることが期待されています。 さらに、非麻薬性鎮痛薬は、特定の疾患に対する治療法としても研究されています。例えば、慢性疼痛症候群や線維筋痛症、神経因性疼痛など、多様な痛みの管理にこれらの薬剤がどのように寄与できるかが探求されています。 最後に、非麻薬性鎮痛薬の使用にあたっては、患者自身が適切な知識を持ち、自己判断での過剰使用を避けることが重要です。また、痛みが持続したり、他の症状が伴った場合には、必ず医療機関に相談することが推奨されます。非麻薬性鎮痛薬は痛みの軽減に役立つ一方で、正しく使用されることがその効果を最大限に引き出すことに繋がります。このように、非麻薬性鎮痛薬は現代の医療において重要な役割を果たしており、患者の生活の質を向上させるための中心的な存在であると言えるでしょう。 |